A Transformative Quarter Unlocking Value & Returning Capital to Shareholders With a Focus on Innovation, Clinical Progress & Long-Term Growth The second quarter of 2026 marked a defining milestone for Cumberland Pharmaceuticals. With the successful completion of our Strategic Transaction, we entered a new chapter as an innovation-focused biopharmaceutical company

  We are off to a strong start in 2026, building on the momentum generated over the past year while entering into a transformational agreement designed to position Cumberland for its next phase of growth. We recently announced a Strategic Transaction with Apotex Inc. to integrate our branded U.S. commercial

We’re delighted to report that 2025 was an outstanding year for Cumberland! We delivered a strong financial performance, expanded our global reach, advanced our clinical programs and added to our commercial portfolio — all while remaining focused on our mission of delivering unique products that improve the quality of patient